Home
clear space
Press Releases Line Publications Line Presentations Line Posters Line

Publications

I-K Park, B Mundy-Bosse, S P Whitman, X Zhang, S L Warner, D J Bearss, W Blum, G Marcucci, and M A Caligiuri. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. June 19, 2015; doi: 10.1038/leu.2015.147. (2015)
Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. Leukemia. Oct 18. doi: 10.1038/leu.2013.298. (2013)
Xiaoping Wang, Hitomi Saso, Takayuki Iwamoto, Weiya Xia, Yun Gong, Lajos Pusztai, Wendy Woodward, James Reuben, Steven Warner, David Bearss, Gabriel Hortobagyi, Mien-Chie Hung, and Naoto Ueno TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Res. Nov 1;73(21):6516-25. doi: 10.1158/0008-5472.CAN-13-0967 (2013)
Fang Xiao, Guido Tricot, Mohamed Salama, Wen Zhou, Hongwei Xu, Shashirekha Shetty, Tiehua Chen, Jiliang Xia, He Wang, Rodney Miles, Caigao Zhong, Maurizio Zangari, David Bearss, and Fenghuang Zhan High Nek2 Induces Drug-resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers. Cancer Cell. 23(1):48-62. PMID: 23328480 (2013)
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan YH, Giri U, Tumula P, Nilsson MB, Gudikote J, Tran HT, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett NL, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes K, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. PMID: 23091115 (2013)
Bearss DJ. Shining the light on aurora-a kinase as a drug target in pancreatic cancer. Mol Cancer Ther. 10(11): 2012 (2011)
Mahalingam D, Espitia CM, Medina EC, Esquivel JA 2nd, Kelly KR, Bearss D, Choy G, Taverna P, Carew JS, Giles FJ, Nawrocki ST. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer. 105(10):1563-73. (2011)
Alexis Mollard, Steven L. Warner, Lee Call, Mark Wade, Jared Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati, David J. Bearss Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors ACS Med. Chem. Lett. DOI: 10.1021/ml200198x (2011)
Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer Kinases in Cancer. Mol Cancer Ther. Oct;10(10):1763-73. (2011)
Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, Sarantopoulos J, Bearss D, Giles F. The Pim Kinases: New Targets for Drug Development. Curr Drug Targets. Jul. 2011.


clear space